Kineta inks $360 million-plus deal with Genentech for chronic pain drug
Kineta Chronic Pain LLC has inked a drug collaboration deal with pharmaceutical giant Genentech to develop non-opioid chronic pain treatment.
The Seattle-based biotech, a subsidiary of Kineta Inc., received an undisclosed upfront payment as part of the deal and is eligible for milestone payments up to $359 million as well as royalty payments.
San Francisco-based Genentech has the option to license technologies developed during the col laboration. Swiss drug maker Roche bought Genentech for $46.8…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Casey Coombs Source Type: news
More News: American Health | Biotechnology | Chronic Pain | Health Management | Pain | Switzerland Health